Literature DB >> 28852252

Psychosis Following Carbimazole-induced Acute Alteration of Hyperthyroid Status.

Guru S Gowda1, Mallikarjun Rao Sagi1, Sai Komal1, T S Jaisoorya1.   

Abstract

Abrupt normalization of hyperthyroid state with antithyroid drugs is reported to precipitate psychosis. We report the development of acute psychosis in a 20-year-old woman, following 30 days use of tablet carbimazole 10 mg for hyperthyroidism due to the multinodular goiter. At the time of presentation, she was euthyroid with a resolution of hyperthyroid status both clinically and biochemically. After 20 days treatment with tablet olanzapine 10 mg/day and stoppage of carbimazole, psychotic symptoms remitted completely and she has since remained in a euthyroid state and free from psychotic symptoms. This case highlights the development of psychosis in individuals, following rapid restoration to normal serum thyroid hormone levels in hyperthyroid individuals with carbimazole.

Entities:  

Keywords:  Carbimazole; euthyroid state; multinodular goiter; psychosis

Year:  2017        PMID: 28852252      PMCID: PMC5560006          DOI: 10.4103/0253-7176.211753

Source DB:  PubMed          Journal:  Indian J Psychol Med        ISSN: 0253-7176


INTRODUCTION

Carbimazole is a prodrug and its active metabolite acts by inhibiting thyroid peroxidase enzyme, hence reduces the thyroid hormone production. It is used in a treatment of hyperthyroid status due to grave disease, thyroiditis, and multinodular goiter. Most people reach a euthyroid state within 4–6 weeks with antithyroid drugs treatment for hyperthyroidism. Abrupt normalization of serum thyroid hormones or hypothyroidism state with antithyroid treatment is reported to precipitate psychosis[1234] and mood disorder.[5] We describe a case of acute psychosis in young female, following rapid normalization of thyroid hormone with carbimazole. Issues of possible pathophysiology, diagnosis, and management are discussed.

CASE REPORT

Ms. S, a 20-year-old single female, from a South Indian family of upper socioeconomic status urban background, was premorbidly well adjusted, with a family history of hypothyroidism in mother and no significant personal history. She had no significant psychiatric history. She was seen by an endocrinologist for the symptoms of sweats, headaches, tremor, palpitations, irregular cycles, and weight loss of approximately 4 kg over the previous 3–4 months. She underwent biochemical investigation [Table 1] and ultrasonography of the neck and was diagnosed with hyperthyroidism due to multinodular goiter and started on tablet carbimazole 10 mg/day.
Table 1

Relation between thyroid hormone and psychosis

Relation between thyroid hormone and psychosis After 30 days of initiation of carbimazole, she started experiencing somatic, tactile, kinesthetic, cenesthetic, and occasional second person auditory hallucinations. She attributed that her abnormal perceptual experiences are due to electronic radiation produced by gadgets used by her, so she started avoiding mobile, computer, and electronic gadgets. These symptoms were also associated with decreased sleep, restlessness, and socio-occupational dysfunction. When she presented to our hospital, the symptoms were present for 3 weeks; hence, a provisional diagnosis of acute psychosis was made. On admission, detailed physical and neurological examinations did not suggest hyper/hypothyroidism features. On the mental status examination, she was restless, anxious and reported somatic, tactile, kinesthetic, cenesthetic, and occasional second person auditory hallucinations. Diagnostic laboratory investigations such as noncontrast computerized tomography - brain, electrocardiogram, electrolytes, renal and liver profile, blood sugar, thyroid hormone function [Table 1], folate, cyanocobalamin, lipid profile, and complete hemogram investigations were normal. Ultrasonography of the thyroid gland shows multinodular goiter feature. In liaison with the endocrinologist, the patient was started on tablet olanzapine 10 mg/day and carbimazole was stopped. All abnormal perceptual experiences, hallucination, fear, sleep difficulties resolved with full recovery in psychosocial functioning in 20 days [Table 1]. She has remained in a euthyroid state and free from psychotic symptoms on follow-up.

DISCUSSION

In our case, the patient developed psychosis around 30 days after initiation of carbimazole. At the onset of psychosis, she had a euthyroid status both clinically and biochemically; hence, it is possibly unlikely that her hyperthyroid status or initiation of carbimazole tablets could have led to precipitation of psychosis. One of the possibilities could be the abrupt alteration of thyroid hormone level in the body and brain precipitated psychosis in our patient. This possibility has been reported prior where an abrupt alteration in thyroid hormone has been reported to precipitate psychosis.[2345] Her psychotic symptoms are resolved completely after with olanzapine treatment and improved to premorbid level.

CONCLUSION

An abrupt alteration of thyroid hormone homeostasis in the brain and body may lead acute psychotic illness individuals, so there needs to exercise caution while rapidly adjusting serum thyroid hormone levels in individual with a thyroid disorder.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

1.  Mood swing from severe depression to mania following acute alteration of thyroid status.

Authors:  Jun-ichi Iga; Takahide Taniguchi; Tetsuro Ohmori
Journal:  Gen Hosp Psychiatry       Date:  2005 Nov-Dec       Impact factor: 3.238

2.  Psychosis following acute alteration of thyroid status.

Authors:  R Irwin; P M Ellis; J Delahunt
Journal:  Aust N Z J Psychiatry       Date:  1997-10       Impact factor: 5.744

3.  Psychosis due to acute hypothyroidism during the administration of carbimazole.

Authors:  C Brewer
Journal:  Br J Psychiatry       Date:  1969-10       Impact factor: 9.319

4.  Psychosis after acute alteration of thyroid status.

Authors:  P D Bewsher; A Q Gardiner; A J Hedley; H C Maclean
Journal:  Psychol Med       Date:  1971-05       Impact factor: 7.723

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.